Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B ...

If all beneficiaries who are eligible for Wegovy were to receive it, it would cost Medicare $34B to $145B annually, depending ...

Discover the perfect opportunity to create your dream home or investment on this expansive approximately 2.72 acres (1.1 ha subject to final survey and registration) parcel of vacant land at 145B ...

The number of patients who will be eligible for Novo Nordisk’s blockbuster GLP-1 under new Medicare Part D plan guidelines will vary depending on how cardiovascular disease is defined, according to ...

Conclusion: Compensation received under Section 28 of the Land Acquisition Act was taxable under section 56(2)(viii) r.w.s 145B(1) as the provisions of section 10(37) deal with ‘compensation’ only and ...